Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment

Beusterien, K; Maculaitis, MC; Hallissey, B; Gaschler, MM; Smith, ML; Law, EH

Law, EH (corresponding author), Pfizer Inc, Global Hlth Econ & Outcomes Res Breast Oncol, Patient & Hlth Impact, 235 E 42nd St,Off 219-06, New York, NY 10017 USA.

PATIENT PREFERENCE AND ADHERENCE, 2021; 15 (): 611

Abstract

Purpose: Several adjuvant phase III trials are evaluating cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) in combination with endocrine therapy (ET)......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索